{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"2.00","value":"1"},{"groupId":"OG001","lowerLimit":"1.00","upperLimit":"5.97","value":"2.02"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"0.00","value":"0.00"},{"groupId":"OG004","lowerLimit":"0.00","upperLimit":"6.00","value":"2.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"title":"Tmax (C1D1)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.00","upperLimit":"3.03","value":"2.50"},{"groupId":"OG001","lowerLimit":"1.00","upperLimit":"1.00","value":"1.00"},{"groupId":"OG002","lowerLimit":"3.47","upperLimit":"3.47","value":"3.47"},{"groupId":"OG003","lowerLimit":"3.03","upperLimit":"3.03","value":"3.03"},{"groupId":"OG004","lowerLimit":"0.98","upperLimit":"4.00","value":"3.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"title":"Tmax (C1D15)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"description":"Tmax was calculated using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) and the LLOQ was 0.100 µg/mL. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed.","dispersionType":"Full Range","groups":[{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG000","title":"Cohort 1: Rhabdomyosarcoma (RMS)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG001","title":"Cohort 3: Ewing Sarcoma/pPNET (Ewing)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG002","title":"Cohort 5: Measurable Neuroblastoma (mNeuroblastoma)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG003","title":"Cohort 6: Evaluable Neuroblastoma (eNeuroblastma)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG004","title":"Cohort 7 (Hepatoblastoma)"}],"paramType":"MEDIAN","populationDescription":"PKES set","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 1 (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose); Cycle 1 Day 15 ± 1 day (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose)","title":"Time to Reach Peak or Maximum Concentration (Tmax) of Pazopanib by Cohort","type":"SECONDARY","unitOfMeasure":"Hours"}